<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00581087</url>
  </required_header>
  <id_info>
    <org_study_id>Dromer</org_study_id>
    <secondary_id>AFSSAPS 040479</secondary_id>
    <nct_id>NCT00581087</nct_id>
  </id_info>
  <brief_title>Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults</brief_title>
  <acronym>DHEA-HTAP</acronym>
  <official_title>Double-blind, Randomised, Placebo-controlled Phase III Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DHEA prevents and reverses chronic hypoxic pulmonary hypertension in a chronic&#xD;
      hypoxic-pulmonary hypertension model in the rat. However, no study has been performed in&#xD;
      human. The purpose of this study is to determine if DHEA is effective in the treatment of&#xD;
      respiratory pulmonary hypertension in adults with Chronic Obstructive Pulmonary Disease&#xD;
      (COPD) on exercise capacity and haemodynamic variables. Patients will receive after&#xD;
      randomization either 200 mg oral DHEA or placebo over a one-year period. Evaluation concerns&#xD;
      clinical parameters, echocardiography and right catheterization after and before treatment.&#xD;
      Primary end-point is the six-minute walk test. This is a prospective double blind,&#xD;
      randomized, placebo controlled study which will be realized in four university hospitals in&#xD;
      France : Bordeaux, Strasbourg, Toulouse and Limoges.&#xD;
&#xD;
      Eight patients with pulmonary hypertension (New York Heart Association functional class III&#xD;
      or IV) associated with COPD were included in a pilot study between 2004 and 2005. Inclusion&#xD;
      criteria were: COPD was defined by FEV1/FVC &lt; 70% of reference values; resting mean pulmonary&#xD;
      artery pressure (assessment by right pulmonary catheterization) ≥ 25mmHg with mean pulmonary&#xD;
      capillary wedge pressure ≤ 15mmHg, PaO2 ≤ 60mmHg at rest or PaO2 ≥ 60mmHg associated with&#xD;
      significant fall in O2 saturation with exercise; oxygen treatment initiated more than six&#xD;
      months previously. Exclusion criteria were: clinical or respiratory instability during the&#xD;
      three months before the inclusion in the study; corticosteroids therapy (&gt; 0.5mg/kg/day of&#xD;
      prednisolone or as equivalent); hepatic (prothrombin time &lt; 50%) or renal (creatininemia &gt;&#xD;
      130µmol/L) failure; diabetes; left ventricular dysfunction; PSA (prostatic antigens &gt;&#xD;
      2,5ng/ml) and past history or diagnosis of cancer. The study was conducted in accordance with&#xD;
      the Good Clinical Practices Guidelines. The study protocol was approved by the ethics review&#xD;
      board of the University Hospital of Bordeaux (France). Written informed consent was obtained&#xD;
      for all patients and investigations were conducted according to the institutional guidelines&#xD;
      and to the Helsinki principles. This trial conducted enrollment between 2004 and 2005, but&#xD;
      had not been registered in ClinicalTrials.gov because it preceded this policy.(Study design:&#xD;
      The dose of oral DHEA administered was 200 mg once daily for three months. At baseline and&#xD;
      after three months of treatment, clinical evaluation included 6MWT, Borg dyspnea index,&#xD;
      systolic and diastolic blood pressure, right heart catheterisation, lung function testing and&#xD;
      serum DHEA levels were performed.)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      • Principal Objective : Efficacy of DHEA on exercise capacity (six-minute walk test)&#xD;
&#xD;
        -  Secondary Objective :&#xD;
&#xD;
             -  Efficacy of DHEA on pulmonary arterial pressures (mean, systolic and diastolic), on&#xD;
                systemic arterial pressures, pulmonary vascular resistances&#xD;
&#xD;
             -  Safety of DHEA treatment&#xD;
&#xD;
             -  Observance of treatment by DHEA&#xD;
&#xD;
        -  Study design :&#xD;
&#xD;
      Double-blind, randomized, placebo-controlled Phase III study. Patients will be randomized&#xD;
      into two parallel groups to receive either 200 mg oral DHEA or placebo over a one-year&#xD;
      treatment. This is a multicentric study in the departments of respiratory medicine of&#xD;
      Bordeaux, Strasbourg, Limoges and Toulouse (France).&#xD;
&#xD;
      • Inclusion criteria :&#xD;
&#xD;
        -  Age ≥ 18 years old and ≤ 75 years old (*)&#xD;
&#xD;
        -  Chronic Obstructive Pulmonary Disease with VEMS/CV &lt; 70% ( **)&#xD;
&#xD;
        -  Respiratory pulmonary hypertension with mean pulmonary arterial pressure ≥ 25 mmHg (**)&#xD;
           related to normal pulmonary capillary pressure assessed by catheterization of the right&#xD;
           side of the heart (pulmonary capillary wedge pressure ≤12mmHg)&#xD;
&#xD;
        -  PO2 ≤ 60 mmHg assessed by arterial gazometry at ease (**) or PO2 &gt; 60 mmHg, but related&#xD;
           with high hypoxemia after exercise (six-minute walk test )&#xD;
&#xD;
        -  Oxygenotherapy more than 6 months before pre-screening&#xD;
&#xD;
        -  Written informed consent&#xD;
&#xD;
      (*) Inclusion of young adults concerns COPD related to asthma or cystic fibrosis (**)&#xD;
      Criteria assessed from last health check or the last exams for COPD diagnosis&#xD;
&#xD;
        -  Exclusion criteria :&#xD;
&#xD;
             -  Clinical instability and/or respiratory exacerbation within the previous three&#xD;
                months&#xD;
&#xD;
             -  Clinical instability and/or respiratory exacerbation dangerous for catheterization&#xD;
&#xD;
             -  Pregnancy (ßHCG &gt; 20 UI /l) or breastfeeding on going&#xD;
&#xD;
             -  General corticotherapy &gt; 0,5 mg/kg/j prédnisolone equivalent&#xD;
&#xD;
             -  Hepatic insufficiency (TP &lt; 50%) or renal insufficiency (creatininemia &gt; 130&#xD;
                µmol/l) or diabetes mellitus type I or II (treated by oral antidiabetic oral or&#xD;
                insulin)&#xD;
&#xD;
             -  Left-heart failure (coronary heart disease and/or left valvulopathy)&#xD;
&#xD;
             -  High level of prostatic specific antigen (PSA) (&gt; 2,5ng/ml)&#xD;
&#xD;
             -  Previous cancer or treatment on going&#xD;
&#xD;
        -  Study plan:&#xD;
&#xD;
      After the screening evaluation and written consent document, patients will be randomized into&#xD;
      two groups placebo or DHEA, over a one year treatment.&#xD;
&#xD;
      • Number of subjects : 60 patients based on the increase of 30 % of the primary end-point,&#xD;
      (six-minute walk test), i.e., 30 patients will be included in each group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>six-minute walk test</measure>
    <time_frame>inclusion and one year of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary and systemic arterial pressures (mean, systolic and diastolic)</measure>
    <time_frame>Inclusion and one after year of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary vascular resistances</measure>
    <time_frame>Inclusion and after one year of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>along one year of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>Along one year of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DHEA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DHEA treatment</intervention_name>
    <description>DHEA : 200 mg/day hard gelatine capsule</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Treatment : 200 mg/day hard gelatine capsule</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old and ≤ 75 years old (*)&#xD;
&#xD;
          -  Chronic Obstructive Pulmonary Disease with FEVs/VC &lt; 70% (**)&#xD;
&#xD;
          -  Respiratory pulmonary hypertension with mean pulmonary arterial pressure ≥ 25 mmHg&#xD;
             (**) related to normal pulmonary capillary pressure assessed by catheterization of the&#xD;
             right side of the heart (pulmonary capillary wedge pressure ≤12mmHg)&#xD;
&#xD;
          -  PO2 ≤ 60 mmHg assessed by arterial gazometry at ease (**) or PO2 &gt; 60 mmHg, but&#xD;
             related with high hypoxemia after exercise (six-minute walk test )&#xD;
&#xD;
          -  Oxygenotherapy more than 6 months before pre-screening&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        (*) Inclusion of young adults concerns COPD related to asthma or cystic fibrosis (**)&#xD;
        Criteria assessed from last health check or the last exams for COPD diagnosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  clinical instability and/or respiratory exacerbation within the previous three months&#xD;
&#xD;
          -  clinical instability and/or respiratory exacerbation dangerous for catheterization&#xD;
&#xD;
          -  Pregnancy (ßHCG &gt; 20 UI /l) or breastfeeding on going&#xD;
&#xD;
          -  General corticotherapy &gt; 0,5 mg/kg/day prédnisolone equivalent&#xD;
&#xD;
          -  Hepatic insufficiency (TP &lt; 50%) or renal insufficiency (creatininemia &gt; 130 µmol/l)&#xD;
             or diabetes mellitus type I or II (treated by oral antidiabetic or insulin)&#xD;
&#xD;
          -  Left-heart failure (coronary heart disease and/or left valvulopathy)&#xD;
&#xD;
          -  High level of prostatic specific antigen (PSA) (&gt; 2,5ng/ml)&#xD;
&#xD;
          -  Cancer antecedent or treatment on going&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire Dromer, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicholas Moore, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Universty Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Dumas De La Roque, Dr</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP hospital Antoine Béclère GHU sud</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Bonnet S, Dumas-de-La-Roque E, Bégueret H, Marthan R, Fayon M, Dos Santos P, Savineau JP, Baulieu EE. Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9488-93. Epub 2003 Jul 23.</citation>
    <PMID>12878719</PMID>
  </reference>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>December 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2007</study_first_posted>
  <last_update_submitted>January 13, 2015</last_update_submitted>
  <last_update_submitted_qc>January 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension, pulmonary</keyword>
  <keyword>DHEA</keyword>
  <keyword>six-minute walk test</keyword>
  <keyword>pulmonary arterial pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

